Targeting IGF1R expression could provide more effective therapeutic benefits in cancer compared to mAbs or TKI since this approach inhibits both the membrane-dependent as well as the membrane-independent functions of the receptor, including its ability to translocate into the nucleus or other intracellular organelles. Here, IGF1R is linked to cancer.